CRISPR Therapeutics AG or Vericel Corporation: Who Manages SG&A Costs Better?

SG&A Cost Management: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. CRISPR Therapeutics AG and Vericel Corporation, two prominent players in the industry, have shown distinct trends in their SG&A expenses over the past decade. From 2014 to 2023, CRISPR Therapeutics AG saw a significant increase in SG&A costs, peaking in 2021 with a 1,900% rise from 2014. However, by 2023, they managed to reduce these expenses by 26% from their peak. In contrast, Vericel Corporation's SG&A expenses grew steadily, culminating in a 780% increase by 2023 compared to 2014. This data highlights the dynamic strategies employed by these companies in managing operational costs, reflecting their adaptability in a rapidly evolving market. Understanding these trends provides valuable insights into the financial health and strategic priorities of these biotech giants.